Introduction
There is an intense eort underway to develop new, more speci®c cancer therapies that target altered genetic pathways in tumours. The bene®t of such therapies lies in the exploitation of these alterations to obtain an improved therapeutic ratio between normal and tumour cells. This eort is contingent upon the identi®cation of an appropriate molecular target, development of modalities that address this target, and delivery of the new agent to the tumour cells. The tumour microenvironment is a critical factor to consider in this development since it can both in¯uence the tumour cell phenotype, and thus the appropriateness of a given molecular target, and act as a barrier for the delivery of eective treatment (Brown and Giaccia, 1998) . For example, the presence of hypoxia is common in human solid tumours and results in signi®cant reductions in the eectiveness of both radiotherapy and chemotherapy (Brown and Giaccia, 1998) . In addition, hypoxia has been shown to produce a selection pressure against apoptotically sensitive cells (Graeber et al., 1996) and is associated with increased metastases of human tumours (Brizel et al., 1996; Hockel et al., 1996) . Thus, the conditions within the tumour microenvironment, including cell-cell contact (3-dimensional growth), hypoxia, pH, nutrient deprivation, etc., result in an additional level of complexity over in vitro systems that must be addressed when determining either the role of speci®c cellular proteins in response to therapy, or the eectiveness of the therapy in dierent tumour cells.
We and others recently identi®ed an example of this complexity in which the role of the cyclindependent kinase inhibitor, p21 waf1 , in radiation response was contingent upon cellular growth in the context of a tumour microenvironment (Waldman et al., 1997; Wouters et al., 1997) . p21 is transactivated by the tumour suppressor p53 in response to genotoxic stress and mediates a G1 cell cycle block that is thought to prevent the replication of damaged DNA. Loss of p21 in human colon carcinoma cells results in cell-cycle checkpoint failure and induction of polyploidy and apoptosis following genotoxic damage (Waldman et al., 1996; Wouters et al., 1997) . When assayed in vitro, the loss of p21 appears to eect the mode of cell death, i.e. apoptosis versus mitotic death, rather than the overall level of cell killing since when survival is determined by clonogenic assay there is no dierence in the sensitivity of p21 +/+ and p21 7/7 cells to radiation, etoposide, or other DNA damaging agents (Fan et al., 1997; Waldman et al., 1997; Wouters et al., 1997) . However, loss of p21 does sensitize tumours to radiation treatment as determined by tumour regrowth delay or by an in vivo/in vitro clonogenic assay. The loss of p21 also causes an increased radiosensitivity to whole-body irradiation in ATM (mutated in ataxia telangiectasia) knockout mice, although no overt sensitivity is seen in the p21 7/7 mice alone (Wang et al., 1997) . The basis of this in vivo speci®c sensitization is unknown. It has been proposed that this in vivo enhancement could be due to the dierent modes of cell death between the wild-type and p21 knockouts (Waldman et al., 1997) . This explanation suggests that apoptosis in the p21 knockouts in¯uences the tumour response because dead cells are removed and cannot promote survival and regrowth of the survivors. In our earlier study of the sensitivity of these p21 7/7 tumours (Wouters et al., 1997) we obtained preliminary evidence that this explanation seemed unlikely and that apoptosis may not be involved.
The purpose of the present study was to investigate the mechanism for the in vivo sensitivity of the p21 7/7 tumours in greater detail. We show that the in vitro phenotype resulting from the loss of p21 cannot account for the sensitivity of the tumours irradiated in vivo. Whereas the in vitro phenotype can be attributed to a lack of p21 induction by p53 following DNA damage, the role of p21 in vivo is independent of p53 transactivation. A further dissociation of the in vitro and in vivo phenotypes is demonstrated by the fact that dramatic changes in the apoptotic response of the tumour do not eect overall tumour sensitivity. Our results from this set of experiments de®ne a new, in vivo speci®c role for p21 in tumour radiation response that is independent of its role in the p53 damage response pathway including apoptosis. These ®ndings therefore imply that p21 may be a therapeutically relevant molecular target for future cancer therapies.
Results
Apoptosis following irradiation in vitro results from failure to transactivate p21 waf1 We introduced the E6 gene from human papillomavirus type 6 into HCT116 human colon cancer cells to abrogate the function of p53, which is wild-type in these cells. Introduction of this gene targets p53 for ubiquitin-dependent proteolysis (Schener et al., 1993) . We identi®ed a stable clone that showed loss of p53 induction following ionizing radiation and that also demonstrated failure to induce p21 following radiation treatment (Figure 1a ). These p53-abrogated cells were then tested in vitro for their response to various anticancer agents including radiation. We examined each of the previously demonstrated phenotypic changes that occur following the loss of p21, namely their cell cycle, apoptotic and clonogenic responses. In all cases, the cells lacking p53 and therefore p53 mediated transactivation of p21, demonstrated a phenotype that was similar to HCT116 cells lacking p21. Following genotoxic damage, loss of either p53 function or p21 in these cells results in failure to initially block at the G1/S border (Figure 1e ), uncouples mitosis and S phase leading to successive rounds of DNA replication without cell division (data not shown) and sensitizes cells to death by apoptosis ( Figure 1b) . Consistent with our earlier data (Wouters et al., 1997) and that of others (Waldman et al., 1997) , sensitization to apoptosis in these cells does not lead to an increased sensitivity as assessed by a clonogenic assay (Figure 1c ). In this assay, the E6 expressing cells exhibit a slightly more radioresistant response in comparison to the wild-type cells. This increased resistance is similar to that observed in the p21 knockout cells, and is likely due to an increased fraction of radioresistant S phase cells. Thus, the in vitro phenotype ascribed to the p21
cells is consistent with a lack of p21 activation in a p53 dependent manner following genotoxic damage.
p21
waf1 mediated tumour radioresistance is independent of p53
We and others previously showed that while loss of p21 fails to sensitize cells to overall cell killing in vitro, it does sensitize tumours derived from these cells when grown in vivo (Waldman et al., 1997; Wouters et al., 1997) . When xenografts from wild-type and knockout cells were grown and irradiated in vivo in immunode®cient mice, the tumours lacking p21 were far more sensitive than their wild-type counterparts as assessed by both clonogenic and regrowth delay experiments. We conducted a similar series of experiments with the HCT116 cells that express E6 to abrogate p53 function. Figure 2 shows the results of a tumour regrowth delay assay using immunode®cient mice containing tumours derived from HCT116 cells, or HCT116 cells expressing E6. The relative tumour volume is plotted as a function of time after irradiation with 7.5 or 15 Gy. In contrast to the results with HCT116 tumours lacking p21 (Figure 2b ), no sensitization is observed in the tumours expressing E6 in comparison to the wild-type tumours. If anything, these p53 de®cient tumours are somewhat more radioresistant. Thus, despite their similar phenotypes in vitro, loss of p53 does not recapitulate the sensitization to overall cell killing resulting from loss of p21 when assayed in vivo. This result dissociates the in vivo role for p21 in the cellular response to radiation from the well-described p53 dependent transactivation that occurs following genotoxic damage. It also implies that the phenotypic changes that are observed in vitro (loss of checkpoint control and increased apoptosis) cannot account for the in vivo sensitization following loss of p21 since these changes occurred in both the p21 7/7 cells as well as in the p21 +/+ cells with abrogated p53. In order to determine whether part of the in vivo speci®c sensitization that occurs following loss of p21 is due to the increased apoptotic potential of these cells, we conducted a series of experiments in which apoptosis was evaluated in tumours irradiated in vivo. Tumours were irradiated with 15 Gy and isolated 4 days later, a time where signi®cant apoptosis can be observed in the p21 7/7 cells after in vitro irradiation. Frozen tissue sections were made from these tumours, and apoptotic cells were detected by TUNEL staining.
As expected the HCT116 wild-type cell line showed no signi®cant apoptosis after irradiation while the p21 knockouts demonstrated a substantial apoptotic response (Figure 3a ± d) . The p21 7/7 tumours also showed evidence of cell loss at this point presumably due to removal of cells that had undergone apoptosis at an earlier time.
We next introduced the anti-apoptotic gene, bcl-2 into the apoptotically sensitive p21 7/7 cells. We evaluated a number of stable clones and chose one that showed a signi®cant reduction in apoptosis in vitro following either etoposide or radiation treatment (Figure 1b) . No dierence in clonogenic survival is observed between the p21 7/7 and p21 7/7 bcl-2 expressing cells (Figure 1d ) despite the signi®cant dierences in the induction of DNA-damage induced apoptosis. This result was not unexpected and was consistent with the lack of correlation observed between apoptotic and clonogenic assays in vitro with the HCT116 wild-type, p21 knockouts, and E6 expressing cells. We next implanted the p21 7/7 cells expressing bcl-2 into immunode®cient mice. When tumours derived from these cells were irradiated, bcl-2 was able to eectively block the apoptotic response that had resulted from loss of p21 (Figure 3g,h ). The importance of this desensitization to apoptosis was subsequently determined by measuring the radiation sensitivity of the p21 7/7 tumours expressing bcl-2. The data in Figure 2d show that despite their reduced apoptotic potential the tumours derived from the bcl-2 expressing cells, if anything, are more sensitive as opposed to more resistant than the parental p21 knockouts. These data indicate that the increased apoptotic potential of the p21 knockouts is not responsible for the increased sensitivity of tumours derived from these cells.
A further con®rmation that apoptosis was not contributing to overall tumour response in these cells was evident from a comparison of the p21 wild-type cells with those that expressed E6. Although expression of E6 in the HCT116 (p21 +/+ ) tumours did not sensitize these tumors to irradiation, it markedly increased the level of apoptosis within the tumour (Figure 3f ), presumably due to the lack of p21 transactivation as was the case in vitro. The clear lack of correlation between treatment sensitivity and apoptotic response in the E6 and bcl-2 expressing cells provides direct evidence that the p21 mediated radiation resistance is independent of the apoptotic response of these tumours. The sensitization to apoptosis observed in the p53-abrogated tumours also indicates that the lack of sensitization to overall killing in these tumours is not a result of a loss of E6 expression and reversion back to the wild-type phenotype.
Discussion
The data presented in this study illustrate two important aspects of tumour sensitivity to cancer treatment. First, they demonstrate that apoptotic sensitivity and overall treatment sensitivity are distinct from each other. There are several examples in the literature where apoptotic sensitivity and clonogenic survival fail to correlate following treatment with DNA ; (e, f) p21 +/+ -E6; (g,h) p21
-Bcl-2. Extensive apoptosis was observed in the radiosensitive p21 7/7 tumours and in the radioresistant p21 +/+ -E6 tumours. The p21 wild-type cell line showed no signi®cant apoptotic response to radiation. Expression of Bcl-2 eectively inhibited the apoptosis observed in the p21 7/7 tumours p21 and cancer therapy BG Wouters et al damaging agents in vitro (Han et al., 1997; Huang et al., 1996; Kyprianou et al., 1997; Lock and Stribinskiene, 1996; Waldman et al., 1997; Westphal et al., 1997; Wouters et al., 1997; Yin and Schimke, 1995) , but this is the ®rst such demonstration for a lack of correlation using isogenic cells grown as tumours in vivo. Although, loss of p21 increased radiation-induced apoptosis and also sensitized tumours to radiation (Figure 2b ), no increase in tumour sensitivity was observed when p53 was abrogated in these same cells despite the fact that this abrogation led to an equivalent increase in apoptosis compared with that seen after loss of p21. Similarly, a reduction in apoptotic potential was achieved in vivo by introducing bcl-2 into the p21 7/7 cells, without any increase in tumour radioresistance. We must conclude therefore, that the loss or gain of apoptotic sensitivity by genetic modulation, such as loss of p53 or p21, can occur without a change in the overall level of tumour killing and thus the expected ecacy of treatment. The loss of p21 in these cells modulates the sensitivity of tumours irrespective of their apoptotic sensitivity. These data highlight the pitfalls of any short-term measurement of cell killing, including measurements of apoptosis. These assays measure only the degree of cell death that occurs within a speci®c`window' of time, or re¯ect only one mode of cell death, and may not be re¯ective of the overall level of cell killing and thus the expected long term tumour response (Brown, 1996) .
The second aspect of importance to cancer therapy is the identi®cation of a unique role for p21 in the cellular response to radiation therapy that is speci®c to the tumour microenvironment. The role of p21 in this regard is outside of the well-de®ned p53/p21 damage response pathway that accounts for the phenotypic changes that occur in these cells in vitro. Loss of p21 or p53 results in loss of checkpoint control, uncoupling of S phase with mitosis leading to polyploidy, and sensitization to apoptosis. Sensitization to apoptosis in the p21 or p53 abrogated cells occurs both in vitro, as well as in cells grown as tumours in vivo. Since each of these phenotypic changes occur in both p53 and p21 abrogated cells, it is reasonable to assume that they result from the failure of p53 to upregulate p21 following DNA damage. Our results indicate that p21 has an additional, in vivo speci®c, role in determining overall cell-killing in the tumour. When these cells are grown as tumours, sensitization to radiation treatment is observed only in the cells that have lost p21. The tumours arising from the cells with abrogated p53 showed increased apoptosis (as expected from the in vitro phenotype), but the overall level of cell-killing is unchanged in comparison to the wild-type cells. This is the ®rst direct evidence that p21 may mediate tumour response to therapy independently of p53. The consequences of this ®nding have potential importance to future cancer therapies because they suggest an opportunity for using p21 as a molecular target. Three important points factor into this potential. First, very few tumours have been shown to contain mutations in p21, and thus targeted inhibition of p21 function would be applicable in most patients (Bhatia et al., 1995; Biggs and Kraft, 1995) . Second, the role of p21 in determining tumour response to radiation is p53-independent. This is of obvious important when considering targeting p21 clinically, since most human tumours contain mutations in p53 and thus lack p53-dependent p21 transactivation following treatment. Our data suggest that targeting p21 in mutant p53 tumours would be as clinically useful as in tumours with wild-type p53. Finally, our data indicate that disruption of p21 would be eective in tumours regardless of their apoptotic sensitivity. Loss of apoptotic sensitivity in response to various genotoxic and non-genotoxic stresses is considered an important process in the development of malignancy (Hartwell and Kastan, 1994; Thompson, 1995) . This loss of apoptotic sensitivity is also widely believed to provide a mechanism of resistance to cancer therapy (Fisher, 1994; Gjerset and Sobel, 1997) . Development of new, more eective therapies thus require either restoration of the ability of tumour cells to undergo apoptosis or the ability to kill cells by an apoptotic independent mechanism. Targeting p21 appears to fall into the latter category since the loss of this gene resulted in the same degree of sensitivity in cells that expressed bcl-2 and failed to undergo apoptosis as it did in tumours in which the primary form of cell death was apoptosis.
Dissociation of the in vivo and in vitro eects of p21 in the response of cells to radiation also highlights the importance of evaluating the role of oncogenes and tumour suppressor genes in the context of the tumour microenvironment. Evaluation in this context will undoubtedly continue to yield results that both further de®ne basic mechanisms in molecular and cellular biology as well as contribute to the rational design of future cancer therapies.
Materials and methods

Cell lines and cell culture
The HCT116 human colon carcinoma cells and a derivative in which both p21
Waf1 alleles have been deleted through targeted homologous recombination (Waldman et al., 1995) were kindly provided by Dr Bert Vogelstein of the John Hopkins Oncology Center. The cell lines were maintained in monolayer culture in McCoy's 5A modi®ed medium supplemented with 10% foetal bovine serum. p53 function was abrogated in HCT116 cells by introducing the human papillomavirus type 6 E6 gene. HCT116 cells were infected with an E6 expressing retrovirus kindly provided by Dr D Galloway of the University of California San Francisco (Halbert et al., 1992) . Stable cell clones were selected and analysed by Westerns for loss of p53 and p21 protein induction following irradiation. HCT116 p21 7/7 -bcl-2 cells were created by transfecting HCT116 p21 7/7 cells with a vector based on the splenic focus-forming virus (SFFV) expressing bcl-2, kindly provided by Dr D Hockenbery of the Fred Hutchinson Cancer Center. This vector has been shown to cause overproduction of bcl-2 with the same cellular distribution pattern as endogenous bcl-2 (Hockenbery et al., 1990) . Stable clones were selected and analysed for loss of apoptotic potential in response to etoposide and irradiation.
Western blot analysis
Total cellular protein was harvested from samples and quantitated by reaction with bicinchoninic acid (Pierce, Rockford, IL, USA). Twenty-®ve mg of protein was separated by 12.5% SDS ± PAGE and subsequently electroblotted onto 0.45-mm nitrocellulose membranes. Membranes were immunoblotted with the monoclonal p53 antibody DO-1 (Oncogene Research Products, Cambridge, MA, USA).
Following incubation with HRP labelled-anti-mouse antibodies, detection was carried out by enhanced chemiluminescence (Amersham, Cleveland, OH, USA). p21 protein levels were determined in the same samples by stripping membranes in 2% SDS, 62.5 mM Tris pH 6.8 buer containing 100 mM b-mercaptoethanol for 30 min followed by immunoblotting with goat polyclonal p21 waf1 antibody (Santa Cruz Biotechnology, CA, USA) and HRP conjugated donkey anti-goat. Detection was carried out in the same manner as for p53.
Apoptosis
Apoptosis was measured in vitro by microscopic visualization following staining with 5 mg/ml propidium iodide, and 5 mg/ ml of bisbenzamide (Hoechst 33342) as previously described (Wouters et al., 1997) . In some instances apoptosis was also quanti®ed by¯ow cytometric analysis (Becton Dickinson FACS-Calibur) using Annexin V staining according to manufacturer's directions (R&D Systems, Minneapolis, MN, USA). Apoptosis was measured in vivo using TUNEL staining (¯uorescein, bright green). Tumours were excised 4 days after irradiation with 15 Gy, and 8 mm frozen tissue sections prepared on poly-L-lysine coated slides. Samples were TUNEL stained with the in situ cell death detection system according to manufacturer's instructions (Boehringer Mannheim), and counterstained with propidium iodide. Stained tissue sections were visualized with a Molecular Dynamics 2010 confocal laser-scanning microscope with an aperture size of 100 mm.
Clonogenic survival
Single-cell suspensions of exponentially growing cells were exposed to varying doses of radiation with a Cs 137 source at *1.5 Gy/min. Following exposure, cells were plated for 14 days, petri dishes were stained and colonies containing greater than 50 cells scored as survivors. The surviving fraction at each dose was calculated as the ratio of survivors in the treated cell populations relative to the untreated controls.
Cell-cycle response
Exponentially growing cells were irradiated with 10 Gy and harvested at dierent time points after exposure. Cells were ®xed in 70% ethanol, washed in PBS, and resuspended in PBS containing 10 mg/ml propidium iodide (PI), and 200 units of ribonuclease A. Following a 30 min incubation at 378C, DNA distributions were determined on a Becton Dickinson FACSCalibur¯ow cytometer. , and p21 7/7 -bcl-2 cells were injected intradermally in the midline of the backs of immunode®cient nude mice and allowed to reach a mean size of 100 mm 3 . Mice with a similar range in tumour sizes were chosen and divided among dierent irradiation groups such that the mean tumour size was the same. Local irradiation of the tumour was carried out using a 250 kVp X-ray source at a dose rate of *1.5 Gy/min with mice placed within individual lead boxes containing a cut-out portion at the rear of each box through which the tumour protruded. The average tumour volume from ®ve mice was determined by measuring each tumour in three orthogonal directions. Volume was estimated as the product of (d 1 .d 2 .d 3 )p/6.
